SPNE - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to the Q2 2019 SeaSpine Holdings Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to introduce your host for today’s call, Leigh Salvo, Investor Relations.

You may begin.

Leigh Salvo

Thank you. participating call. for you thank in today’s And

XXXX. Joining CFO, released John SeaSpine is June full Valentine; and CEO, Keith XX, ended Bostjancic. quarter results the me for from financial second Earlier today, SeaSpine

fact meaning statements During this conference plans, forward-looking business words securities and we’ll are future make our our All of objectives in to other expectations operations conditions. intend of and could, financial statements within regard our and Such forward-looking laws strategy, may federal as statements expressions. such call, historical would, the than and for plan, statements will, statements. future similar results include believe,

information to predictions, as of and You not place are only reliance today, August which and X, on cautioned beliefs forward-looking XXXX. our are current speak statements, reflect only undue on based

and description statements, www.sec.gov. a actual our by and For could that risks see on and SEC, uncertainties our please differences website our filings the of cause at or at corporate between material releases www.seaspine.com which are those periodic implied forward-looking with available stated the results and news

turn now call I’ll Keith? Keith over Valentine. the to

Keith Valentine

Thank marked and Leigh. solid strong us. another We revenue Good quarter for thank expansion. afternoon, had all you, you growth margin continued joining gross overall by and

XXXX. translate our increasing highly products in dates accelerated well of investments made of of systems. with we our the the exclusive continued new am of utilized have We as are in energized spinal by second the revenue more into portfolio, that will line most product and deployment onboarding I sets launch confident the growth distributors, half along additional extensions of our as ongoing implant the

in revenue reflecting X% quarter for strong the to third million, July, spinal XXXX a to revenue, year of raising our year-over-year and start Based implant to guidance growth on million $XXX X.X%. we bullishness are a we particularly range $XXX this full U.S. to saw of

XXXX higher the expectations. totaled increasingly by driven quarter $XX.X Revenue the once performance. exclusive more and our led our of implant of was X% the revenue. growth of versus period, million, top contributed our revenue year-ago In to our increase sales U.S., for that products with more distributors. of line Turning U.S. extensions an of second again our more line line XX% U.S. than than launched and including recently were spinal products, by XX% These orthobiologics in

full-scale past and implant platform the we a spinal years, made towards what foundational reliable of several progress delivering efficient Over systems have we believe orthobiologics innovative, production. to support and consistent processes is

to by make product meaningful surgeon and investments that’s and In continue programs. innovation addition, supported training further we education expanded distributors,

distribution. increasingly As high-quality to give distribution a larger additional and can which result, confidence will in support business, were turn, able that attracts the the growth exclusive our we their of we network and

Turning to product launches.

development and is long-term commitment delivering. One to a market. systems an and key aggressive of a growth commercialization inventory development priorities deep the investment and to our of products and team product delivering We and an launch the SeaSpine year timely sufficient with for of differentiated this into is made sets number penetration the drive rollout, in new

integrated surface seamlessly hydration blood, patented and to Some proprietary System our which surgeon of Mariner that in Demineralized allow I’ll Shoreline more system; OsteoStrand bone and graft syringe Cervical RT minute; aspirate in surface NanoMetalene saline healing and featuring fully NanoMetalene describe a body’s system accelerated Bone marrow the Topography, bone open-bore technology of launch Interbody a products Reef full harnesses convenient launch for introduction Mariner the the highlights limited Outrigger XXX(k) modular DBM Mariner of OsteoStrand platform the and in received Fibers the our Lateral we’re Plus OsteoCurrent with FDA drives our an And ceramic include; System, system, of we System, July. featuring technology; of substitute planning Regatta MIS the and a launch that formation; or response our complex that surface fibers bone the our which slightly structure of cases. clearance new a hydrate the for with a addresses Revision ahead, submicron limited looking expansion

is of act fusion for Reef Reef is grow marry in machined a the potential technology Topography, Topography, are a increased NanoMetalene Reef Reef for RT procedures. have believe additional during Topography NanoMetalene. XXXX. of to as technology new use We enhance end surface advancement across which the mentioned that endplate new pending area the entire that we XX% anticipate the and an to interbody Reef our explicitly in designed provides NanoMetalene describes and interbody address five to demand first series technology and deploy helps of integrated fusion features implants Shoreline and our with scaffolding orthobiologics undercut that implant. proprietary this growing intend Topography and products with bone significant and onto benefit microstructures I the represents exciting high-cost licensed that to an reduce products will products. portfolio our interbody the by NanoMetalene for of into launching and technology we the

foundational particular Outrigger our cortical Mariner and be have open, revenue in these we growth additional support I will to modular close that significant of beginning in continues also important to procedures. procedures launch MIS our leveraged as midline future surgeries. to of as half launches from expect and important our XXXX. to drivers on mention will the Mariner degenerative of received an gap MIS, of second to with market Based invasive the the for want portfolio Mariner share Mariner to The minimally be commercialization platform capturing market and feedback well invasive revision and for we’ve approaches degenerative shift as in all catalysts minimally more surgeons both distributors, we

that products surgical of procedures we comprehensive a robust surgeon capture Collectively, range product spectrum Looking out new a further enable we I’m of the about will will believe to portfolio launches. need opportunity for address case over additional of which excited us to these months, the next a deliver that through XX compete. our full innovate will

Some screw and interbody and and over anterior fixation I’ve TLIF interbody expect insert-and-rotate plate Topography and and with NanoMetalene to an mentioned, techniques; and that Reef that both an the a straight option. months next includes for of no-profile just PLIF contact which an interbody TLIF optional both accommodates includes: interbody device maximize approaches designed a device in-line boarded endplate articulating sagittal XX can modular including incorporate correction; a and you that lumbar impaction the

Vu will pedicle-based modular screw system Mariner anterior limited and with that disc Prime franchise anterior TLIF also support our our instrument interbody the preparation launches a We be plan compatible minimally of better a and lumbar designed NanoMetalene sets; comprehensive newly invasive, next-generation and aPOD existing A-list to retractor decompression implants.

acquired with our technology also Expandable and we a to direction strategy We’ve taken NLT respect Interbody the from Spine. new

with implant. continue move development to efforts We commercialization and NLT forward lordotic the expandable for the

and to robust interbody necessary due identified the in more competitive we market more NLT However, be to expanding to market, development an personal have the features to what even enable. a trends launch initiative and expandable new parallel and cost-effective compared internal technology faster

the launch XXXX. the in make expect first parallel devices half lordotic We both for and of expanding to the

I franchise. with complex to address plans want respect our to spine also and deformity

cases last improved and posted revenue of in development quarter, to will sales. the SeaSpine-branded introduce our our did introduction further see with of though the to rebound Mariner growth and step expanded market-leading nice half deformity franchise in July’s on deformity implant significant second XXXX. its of once in with implant Mariner expect address that again While options, our strong more significant A deformity commercialization our advancement in be in-licensed all Jazz well lower we recent of Outrigger and as posted the brand, compared which enhancements, franchise version take to complex will instrumentation we deformities. both allow as capabilities us year, combined a degenerative Those the and franchise reduction the System, our of second of complex

we that extend in expect similar larger of second so platform extensive on efforts produce additions we will a experienced launch great further this to These have as proceed our our advancements XXXX. franchise deformity to portfolio. Mariner far we confidence these in platform, that Mariner degenerative in have foundational the growth success more will into a and of the the revenue of deformities development Based half deal

time see, you and development talent As we can surgeon and But of capability meet and of on our customers. that demanding I marketing have the commercialization development and in confidence deliver plans. launches aggressive have quality product the teams to needs our great

over John? the provide I’ll John financials then call I our to our outlook, now and on detail more to will up. wrap financial turn

John Bostjancic

and Keith, everyone. Thanks, good afternoon,

increase million, of U.S. on strength X.X% compared million, revenue implant orders. total quarter earlier, noted and of was the XXXX $XX.X an $XX.X second largely prior for revenue As spinal the Keith XX.X% million, of replenishment grew to revenue increased to $X.X to international the year. X%

orthobiologics driven second increased by in the OsteoStrand Plus products, recently year-over-year growth X.X% to revenue million, led product. $XX.X by U.S. quarter the launched DBM in

line of Sales stabilized franchise the a in space expected flow starting desired of graft DBM half products our continue longer-term gross As of of down substitute management the This and to second production products we’re recently our in scale with cannibalization product particulate legacy capacity impact addition broaden growth in marketing synthetic second sales quarter, we product May, will the fiber more expect controlled XXXX. cannibalization our Mozaik collagen the our as margins see production our we have we of the of to to matrix up OsteoCurrent and ramp launched time. of and and in generate products. the ceramic on DBM beneficial bone the over legacy and efforts, cash

and as deformity but somewhat NanoMetalene increased launched systems quarter increased the by single-digit to driven and our once Shoreline implant lower volumes more declines complex and led revenue the and Keith procedural earlier. more in low by spinal products, $XX.X mix, offset mentioned Mariner surgery case portfolio. by Spinal in was U.S. spine price than growth again recently the expanded revenue, XX% year-over-year and were second specifically primarily X.X% implant million by

material and which to Irvine, sold. Gross lowered our benefits margin increased was benefit that XX.X% compared a rates, yields orthobiologics that implemented same reflects series lower-cost the products. of are the scrap as quarter the improvements California P&L the costs of Throughout of raw for period now focused XX% the facility our This manufacturing we realizing and inventory we manufacturing for XXXX. expansion second to efforts in of in reduce manufacturing our at XXXX, is process the

The Interbody outlined. to development million award salaries result costs expenses increased remaining expenses, same and to assets commercialization intangible related compensation was of strategy with the $X from period wages. Research for and Expandable to million of selling, compared and to due totaled million increase due acquisition higher included $XX related commissions, prior stock-based charge NLT costs increase in $X.X and $XX Keith of our higher million year. the second associated shift clinical of selling that Operating a the The XXXX to headcount for and impairment quarter general equity administrative the primarily in primarily studies. $XXX,XXX noncash the including approximately our increased timing grants Spine

$X.X Net of for the of loss charge loss I’d $X million $XX was XXXX, impact reflecting of second million noted. the compared just the quarter a impairment net to million

XXXX, amounts our Cash, at XX, we equivalents facility. $XX.X cash had totaled no investments credit and million, June under outstanding and

in anticipate under utilizing any we we XXXX, nor near not the in the stock program of shares common Year-to-date our did program do sell ATM ATM future.

full in was and excludes cash by compared was year recapped in the full higher inventory both outflows $X.X support numerous and the the of free prior for and to period. million which purchases quarter legacy the securities, fibers-based particulate inflows above commercial $X.X system second of sales driven launch marketable inventory the the Regatta launches to DMB full burn, support and for portfolios. XXXX and preparation purchases to and increase million and newer for DBM of Our primarily of instruments The levels flow the Keith financing

the and finished the the legacy As to orthobiologics’ levels expect in raw reduce second increases, goods of half material products of XXXX. cannibalization DBM we expected

expanding continuing and cash-based margin percentage We gross as expenses our reduce on G&A a of focused revenue. remain to

that are sustained, of growth R&D in achieve However, in the building a implant increased set redeploy and leverage marketing in as sales, free term, needed and short a spinal revenue we that as to towards inventory flow. to are sustained the investments the builds much the plan driving critical scale positive cash continue to initiatives well that operating to

$XX cash million Accordingly, to full expect burn year million. we the of $XX be range free our XXXX flow for to in

That inventory, system and the we implant With and respect of to in will flagship systems. capital spend set expenditures inventory expect in the to to to much spend additional of all that Mariner but sets a and translate of quantify go implant deployment XXXX of to launches in harder nearly will sets. discussed year spinal meaningfully excess Shoreline of this into XX% million support spend compared investments increase $XX earlier represents higher on XXXX. builds That in those in the our capital

wanted per set unmet believe deployments spend and Shoreline particular. the in because there that XXXX on set. for analysis Accordingly, identified we of of drive revenue sets additional a believe systems of this half between of set key spinal systems, I deployment on full growth factor key key revenue and increase as to led detailed launches and it new generated the end investment first growth half We well the implant XXXX, anticipated an as color system give of systems compared our demand strong us a Mariner by top spinal as the XXXX more beginning additions bottom second in to and to revenue meaningful will Based of proven the year we of is the increased revenue aggressive guidance. correlation year. is since measured in greater important implant

outlook XXXX. Turning for to financial our

X% million reflecting over As bottom $XXX revenue revenue of to compares to guidance to million, the Keith we top expectations of year XXXX growth $XXX previous in full now be X.X% mentioned and expect are year of This XXXX earlier, end and our million revenue. $XXX full the $XXX revenue range to of to raising million.

the down P&L. Moving

stock-based changes of XXXX and we’ve of margin as to noncash noncash we and continue and to to to XX% or a excluding improvements We of to losses to process revenue. consideration XX% yield in SG&A, continue gains XX% range the expect gross for fair the to benefits XX% increase the realize within Irvine; charges implemented liabilities, approximate in any related value NLT-contingent compensation to of

revenue increased R&D to and XX% of expect investment to headcount. We reflect approximate development product studies to X% in clinical the

Keith I call over like At turn back the this closing to would comments. for point, to

Keith Valentine

Thank John. you,

both market significantly our share delivering opportunity spine procedural this remain the market. surgeons and We ahead focusing expand that with in have competitive tremendous relevant, to in us clinically distributors on $XX we cost-effective as relentlessly solutions billion-plus differentiate

and least rate to XXx a We the overall continuing our confident are in at committed to are grow to faster than that is ability market spine at execute.

that for start to expand energized the supported differentiated we our We be the half in leverage orthobiologics, foundation in pipeline are devices of I am off a second launches have solid instrumentation our of nearly for and interbody technologies well continue of global are pivotal the the in XXXX, network. organization we but spinal modular will and sustainable as discussed many competencies complementary today solid providing systems. XXX the which to have on distributor as established, reach is the proud We growth high-quality, to we product and and exclusivity employees must others SeaSpine. execute our year of by committed who to continue core numerous

With it that, will Operator? questions. we to up now open

Operator

Instructions] comes from line [Operator Matthew Piper question Our of O’Brien first the Jaffray. with

is open. line Your

Matthew O’Brien

Thanks for on and quarter. the question congrats taking the

Keith Valentine

Good afternoon.

Matthew O’Brien

bit half love back a Good confidence. little Would afternoon, to guys. more about the hear

sure you’ve Those new I’m all these while take a comps products lot got typically coming to and these up. getting ramp which you deployments. little tougher, Your are know, really a but set

you talk really this that. or about sets? what or systems two saying, one all just confidence? existing Or bit little or one looking can you it systems, hey, gives accounts to more or a the these it forward additional is that I’m So Is two

John Bostjancic

analysis couple the constant add It’s deployments, said Yes. much It’s set set revenue a at Matt. generated per right? things, the of That looked as pretty sets. additional we that we stays

they’re year, starting So those revenue. right? of to we’re going onboarded more distributors need more this have And sets. the their in to a incremental – an increase ramps, seeing so We’ve hit exclusive couple to they’re of

those timeliness to critical deployment is the the growth. So of really

big one portfolio closing the MIS And gaps. remaining Mariner of just the of kind

lot think in work needed go sidelines piece a there’s but think folks I us that of with solution, the on and that’s the of kind puzzle just who been of to I final place. the ready have kind MIS of to

that’s optimism So it’s the all for in of half those to the back the year. the contributing factors accelerated growth of

Matthew O’Brien

then… And Okay.

Keith Valentine

One additional one, Matt.

it a you important MIS cortical typically, I – bigger open a It market. of – becomes midline market as But think is more of the very it’s but was that a more whether have MIS it does of important know, to progressively It of probably the fastest-growing note and not the going have important have also strategic. excitement part people the very full Mariner think or and premium, nice system, into the after often distributors to coming accounts door. as about an launch our also becoming well the of It’s the MIS the the MIS, have distributors only as part part bigger entering but really the are we is new added part can mini that MIS. and it’s through area.

them with And our a exclusive part becoming different channel. we have about of conversation

into at add, strategic this an half I So the XXXX. time comes second it important but think was we a we knew of very get as

Matthew O’Brien

the Thanks, on about especially Interesting. lines the hardware along business, the Sticking side. the health Keith. those of –

things down the a bit. mentioned summer given in which surprising here little little that months You this and slow tend is a July just we’re strength, to

strength you from? it deeper accounts? So existing going accounts are in that seeing Is new where come

– and is generally a And player, – is I then but like just it getting generally feels spine, know speaking, smaller market better. the you’re in

sound doesn’t becoming can to there’s if Are a moment? pricing pressure things of the is a you there sector of tailwind a at other less couple are So bit point to. a it things that I’m headwind. like little of wondering It the whole

Keith Valentine

customers in of to it, on the for feel very Matt, not it transparent appears on July. And certain did business, QX. enough, wanted specifically, traditional deformity challenges exactly side scheduling that the the We interestingly but it show of, patients But June. we mention so on, like went of deformity, a of why because had in fully went they July in Yes. we’re some instead strength that were being we of deformity just the

it When of I that it we would comes as categorize the mentioned, to both. other parts July

and the with seeing business. existing accounts degenerative with we’re seeing new We’re strength strength accounts on traditional

So good that’s agree Yes, I sign. you. a with

I think of QX, And the been fact always strong. history I that if you has look concern. at the point certainly QX of like off caution it’s kicking a or

Matthew O’Brien

Got have that that it. I sets gross you’re improvements mean, with quarter, And then, saw little may the that more how process as I these of But a durability metric the as inventory, John, that this this improvement does you’re some bit. of doing adding trend you missed and margin new well?

John Bostjancic

Yes.

of benefit the on give the process a lift to improvements continue expect margin. the us in to We Irvine

balance create pullback levels bringing I fixed lower the portfolio because those the as know, levels it legacy continues sustainable. the in the will right I gross newer with ramp plant the that DBM also we’ll upside fiber-based we inventory to think costs on think of margin increase a – all to but as in But but little cash as would the trying management down. because get be we bit we’re to that inventory cannibalized, up don’t absorption balance legacy portfolio of the more it’s the in because work product the expect to DBM I sales –

Matthew O’Brien

much. Got so it. Thanks

John Bostjancic

Matt. Thanks,

Keith Valentine

Thanks, Matt.

Operator

comes of Our BTIG. with line Zimmerman from next question the Ryan

open. is line Your

Sam Brodovsky

going Thanks. Ryan. How it actually This on Sam guys? is for is

Keith Valentine

Good. going, How’s Sam? it

Sam Brodovsky

good Good. Congrats a on quarter.

new in your the would been generally. to you’ve With of from some work a how we’ve And consolidation seen are industry market feedback on Just been say segments in customers? the you the question new with market, responding? your customer accounts seeing what’s and the ability

Keith Valentine

strong us. Yes. for say it’s a opportunity I still

generally already conversations new all strong for we’re think with that with have there a base company. it’s not who time lack their the think And of to just I big reported. are with distribution, I that a good a former opportunity consolidation on, lack frustrated biggest but going any maybe a surgeons least at conversations of familiar having players still little be having relationship often or also seems the of only there’s communication with

the our very have that’s and kind think that be understanding more offering And those best navigate been and engaged not distribution marketplace, them in to the opportunity. senior we through a and after going make a engaged to that and they’re fact sure conversations team of the I aware a aggressive so different, ability to I we development, in of we’re addition going – and of marketing think, only that very have focused

Sam Brodovsky

this launch, the at forward? a just there. the portfolio at in the you then there’s else be And for But in-house lacking anything external development you’re And feel big Great. going feel that following will looking Mariner at piece coming the looking portfolio or that be do that’s you from, big, whether point? that do where

Keith Valentine

Yes.

there’s the would So – would organic-based, pretty and with of a things couple we elaborate and be project cervical. be moving-forward a posterior have organic-based that

Integra. systems of aware, two you may SeaSpine As we acquisitions each by cervical that and the Theken came from posterior be original have

design and system. we early really even are of a feel on updating, the And version and made our need first done team of the that so with the cadaver system. lab good about in We’ve of developmental those already we’ve progress the

about progress there. So we good feel the

in for the would to areas not that more be the And a we’re time there. navigate fully trying area, is which replacement. part The has we’re when sets is lines vertebral and very body about with time to is how The well-paying an the other set area complex procedure. difficulty is in figure a area it that good short a ability because trauma, spine trauma be that’s out deployment of it’s the quick forward. best that the put investment to The need for it often, the

regions of sit they’re may the and until to weeks basically need and So for country have around deployment requested. in weeks that you

from R&D so – it’s challenge not a little that’s And a bit perspective. an

do to deploy We capital area. have horsepower the more want when our It’s do of particular that to it. we for

Sam Brodovsky

Thank you. Great.

Operator

Instructions] question [Operator the of Ladenburg Thalmann. with comes Thank Our you. from Jeffrey next line Cohen

line Your is open.

Jeffrey Cohen

Hi, How are John. and you? Keith

Keith Valentine

Good. How are you?

John Bostjancic

Jeff. Hi,

Jeffrey Cohen

fine. Just

since have done with the Jazz So cases spring? the in any announcement you the firstly, system

Keith Valentine

couple of, a working So There’s components a, it. that been of that There’s matter to the couple been a our marketplace. think integrating. we system. some It’s there’s one one own people the I traditional proprietary seen on. Jazz have to There’s system, – versions a in there’s are that’s different that will be Mariner

there’s pieces But system, couple yet. different proprietary to that. But not So with system, in Mariner, light the connection the fully yes. launched traditional a of that that’s

Jeffrey Cohen

you out? when of be expect sets some And Okay. those to do

Keith Valentine

I’m you what? sorry, some when do expect

Jeffrey Cohen

Some available that’s be those When compatible? to Mariner to expect with you sets be out? do of that

Keith Valentine

Yes. Yes.

previous bets a schedule. number We shown good success a should screw of get we and also they’ve on don’t any in hangups. we track – fourth and things are already our system, a XXXX, be that need record on feel integration should of place But with there major placing to of quarter buildout. It’s with and clearances like be approvals between so everything feel

Jeffrey Cohen

little half-ish two biologics know as takes are probably throughput running going What’s Okay. is And over seeing past kind higher? there. the in How the I at talk quarter a bit and Got can changes any the capacity as that far you facility as And Irvine you’re max about you things? it. pickup or of hold? changed?

John Bostjancic

materially It’s same. the No.

of around we’ve being production much because just overall, really both full XX% the from process that with efficient because on capacity. we particulate. we’re moved to of just improvements and plant’s made now, the up efficiencies, we’re bore capacity-wise, the legacy DBM XX% haven’t But fibers-based more the think I the at

Keith Valentine

Yes.

too, and really you that should and Jeff, done job. good think, know our manufacturing the team development team, I they’ve between engineering a

really The task make Strand we’ve our feel to on refining really we now, the step folks kind sure really efficient. of looked we to we efficacy. step. have every previous an that launch to process. process process more is And Strand of out the was them put mentioned are product’s as that And at we’re first the now calls first differentiated energy – the important able same And because we manufacturing spend making first that’s maximize let’s the

the it first the best was steps. the in let’s right And goal marketplace the with make product

Next decades really and how in part improvements let’s the we we’ve made manufacture, more make that efficient for make is process products, evaluate light really goes it two of at we way a take it efficacious. some these look to back let’s more

And exciting probably as the so of ‘XX. get that’s in part we most the second half

see We’re really those starting to in both areas. gains of some

Jeffrey Cohen

seen. Got you’ve about seeing there Okay. and of you’ve cross-selling volumes about case talk synergies cetera? Could And as facilities, lastly a little then bit far you it. of that been et number metrics talk as pickup that number Any surgeons, months? the any also on with past few

John Bostjancic

up XX% the in are was about Year-to-date, volumes It case first quarter. Yes. XX%.

is shift. there mix bit of script, a the in outlined a we’d little As

we’re just into And low declines. think of move in of because we with the volume’s decrease the down half So revenue deformity the as distribution growth digits all up the we’re year, there. stay But the new that we’ll mid-double volume single-digit, that in over new pricing was sets that I then back the back year. adding and we mix the deploying of half the feel that good with procedural the

Jeffrey Cohen

Okay. cross-selling biologics between hardware? any and it. And the commentary the Got on

Keith Valentine

significant think, important. I a – continues, the products. I think, extremely is Yes. in trend that now to of Actually, examples newer cross-selling of, have which, especially see we with number And strength exclusive distributors, strength continue the the opportunity, we

with more aboard, technology. with now an seeing reef even stranded interest and coming from especially and also NanoMetalene – more increased comparing new groups, We’re groups technology our NanoMetalene

only that – implant economic any it much that with better at strong not because in as create us, will is, result combination So better demonstrates having DBM to along feel friendly a a a other the cross-selling ultimate a orthobiologically strongly opportunity. we

Jeffrey Cohen

Perfect.

for me. questions. Thanks taking the it that Okay, does for

Keith Valentine

Yes, thank you.

John Bostjancic

Thanks, Jeff.

Operator

queue. I’m closing. like back Valentine to showing further Keith the for call to questions I in over no would now turn the

Keith Valentine

everyone, great have hope and call, you, thank you for for us all a evening. this I So joining Cheers.

Operator

Thank call. today’s you gentlemen, participating. that for and concludes Ladies

You may wonderful day. now have Everyone, disconnect. a

SeaSpine (SPNE) 2 Aug 192019 Q2 Earnings call transcript